AI-generated · cited to primary sources · not investment advice
Viyash Scientific (512529) Nov 2025 Filing Analysis
Does management do what it says?
The company has significantly surpassed the 'high teens' target, achieving a 21% EBITDA margin in the first reported quarter of the merged entity. (2 exceeded, 3 met across 5 tracked commitments)
“You would recall that a few quarters ago, we had set ourselves a target of crossing 15% EBITDA and moving to high teens. We are now firmly on that path while also improving our profit after tax substantially.”
Management confirmed that the field force expansion to 200 personnel in the previous year is now yielding results in the Indian Animal Health segment. (1 met across 1 tracked commitment)
“We expect the impact of our field force expansion to kick in during the second half of the year. As we have said earlier, India remains a key market for us to develop.”
See the full cited Management analysis of Viyash Scientific
How durable is the business?
The regulatory moat is being reinforced with the combined entity now having 16 manufacturing facilities (7 from SeQuent and 9 from Viyash) with major global approvals. (1 expanding)
“SeQuent has seven manufacturing facilities... Viyash has 9 USFDA-approved plants”
See the full cited Business Model analysis of Viyash Scientific
What could break the thesis?
The risk is easing as the company reported a 270-bps improvement in gross margin and a significant rise in EBITDA margins to 15.5%, suggesting one-time costs are being absorbed by operational gains. (2 easing)
“there was a 270-bps improvement in gross margin, and the pre-ESOP EBITDA rose to INR657 million, and that came in at a 15.5% EBITDA.”
The risk is easing as management indicates that dependency on the U.S. is limited (35% of business) and they are protected by having local U.S. manufacturing. (1 easing)
“our dependency on U.S. is not much. So only 35% of the U.S. business, we do formulation. That's, of course, it's a good scenario since we have manufacturing at U.S.”
See the full cited Risk analysis of Viyash Scientific
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.